drugset / Trial / NCT00025415
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction
NaSingle-groupOpen-labelTreatment
Summary
Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase I trial to study the effectiveness of imatinib mesylate in treating patients who have advanced cancer and liver dysfunction
Timeline
- Start
- 2001-08
- Primary completion
- 2005-01
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Imatinib | Small molecule | — | Oral |
Indications
AIDS-related primary central nervous system lymphoma
Burkitt lymphoma
Hodgkins lymphoma
MALT lymphoma
T-cell large granular lymphocyte leukemia
Waldenstrom macroglobulinemia
acquired polycythemia vera
acute undifferentiated leukemia
adult T-cell leukemia/lymphoma
adult acute lymphoblastic leukemia
anaplastic large cell lymphoma
angioimmunoblastic T-cell lymphoma
atypical chronic myeloid leukemia, BCR-ABL1 negative
blast phase chronic myelogenous leukemia, BCR-ABL1 positive
central nervous system non-hodgkin lymphoma
childhood myelodysplastic syndrome
chronic eosinophilic leukemia
chronic lymphocytic leukemia/small lymphocytic lymphoma
chronic myelomonocytic leukemia
chronic neutrophilic leukemia
diffuse large B-cell lymphoma
essential thrombocythemia
extramedullary plasmacytoma
gastrointestinal stromal tumor
immunodeficiency-associated lymphoproliferative disease
intraocular lymphoma
large-cell immunoblastic lymphoma
leukemia, myeloid, accelerated-phase
mantle cell lymphoma
monoclonal gammopathy of uncertain significance
mycosis fungoides and variants
myeloproliferative neoplasm, unclassifiable
nodal marginal zone B-cell lymphoma
plasma cell myeloma
primary myelofibrosis
primary plasmacytoma of the bone
primary systemic amyloidosis
prolymphocytic leukemia
refractory hairy cell leukemia
small intestine lymphoma
splenic marginal zone lymphoma